Last updated: February 19, 2026
What is the Core Subject Matter of Patent AR070561?
Patent application AR070561, filed by Merck Sharp & Dohme Corp., claims a pharmaceutical composition containing Darolutamide in a specific salt form, N-{(2S)-1-[6-(3-chloro-4-fluorophenyl)-2-methylpyrimidin-4-yl]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)pyridin-2-amine, or a pharmaceutically acceptable salt thereof. The composition is formulated for treating or preventing prostate cancer. Specifically, the patent focuses on the use of Darolutamide, an androgen receptor inhibitor, in a crystalline form that exhibits particular physicochemical properties beneficial for drug formulation and delivery. The claimed invention addresses the challenges associated with the solubility, stability, and bioavailability of active pharmaceutical ingredients, aiming to provide an improved therapeutic option for patients with prostate cancer.
What are the Key Claims within Patent AR070561?
The patent's claims delineate the scope of protection for Merck Sharp & Dohme Corp. These claims are central to understanding the exclusivity granted by the patent and its potential impact on market competition.
Claim 1: The Primary Composition
Claim 1 defines the core of the invention: a pharmaceutical composition comprising:
- (A) N-{(2S)-1-[6-(3-chloro-4-fluorophenyl)-2-methylpyrimidin-4-yl]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)pyridin-2-amine (Darolutamide) or a pharmaceutically acceptable salt thereof.
- (B) A crystalline form of Darolutamide, characterized by specific X-ray powder diffraction (XRPD) data, including at least three characteristic peaks at diffraction angles 2θ (±0.2° 2θ): 8.5, 15.9, and 20.7.
- (C) One or more pharmaceutically acceptable excipients.
This claim is broad in its scope, covering the active pharmaceutical ingredient (API) in a defined crystalline form, along with standard pharmaceutical formulation components. The specificity of the XRPD data aims to define a particular polymorphic form of Darolutamide, which is critical for ensuring consistent drug properties.
Claim 2: Enhanced Crystal Form Specification
Claim 2 further refines the crystalline form by specifying additional characteristic peaks in the XRPD pattern: 7.7, 12.4, and 23.1 (±0.2° 2θ). This level of detail aims to more narrowly define the intended crystalline form, potentially excluding other known or potential polymorphs. This specificity can be crucial in patent litigation to distinguish the claimed form from prior art or competitor products.
Claim 3: Identification of a Specific Polymorph
Claim 3 explicitly identifies the crystalline form as Darolutamide Form I. This designation provides a clear label for the specific polymorphic state being claimed, allowing for easier reference and comparison within scientific and legal contexts.
Claim 4: Therapeutic Use of the Composition
Claim 4 pertains to the use of the pharmaceutical composition described in Claim 1, 2, or 3 for the treatment or prevention of prostate cancer. This claim extends the patent protection beyond the composition itself to its specific therapeutic application.
Claim 5: Method of Treatment
Claim 5 outlines a method of treating or preventing prostate cancer comprising administering a therapeutically effective amount of the pharmaceutical composition defined in any of the preceding claims to a subject in need thereof. This method claim provides another layer of protection, covering the act of using the patented composition for its intended medical purpose.
Claim 6: Pharmaceutical Salt Form
Claim 6 focuses on a specific pharmaceutically acceptable salt of N-{(2S)-1-[6-(3-chloro-4-fluorophenyl)-2-methylpyrimidin-4-yl]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)pyridin-2-amine. While the core patent application may focus on the free base or specific crystalline forms, this claim broadens the scope to include salt forms, which can have different physicochemical properties and patentability considerations.
What is the Global Patent Landscape for Darolutamide?
The patent landscape for Darolutamide is multifaceted, with key patents held by Bayer Pharma AG (the originator company for Nubeqa, the brand name for Darolutamide) and its affiliates. Merck Sharp & Dohme Corp.'s involvement with patent AR070561 suggests a potential strategic interest, possibly related to formulation development, alternative crystalline forms, or strategic positioning within the broader Darolutamide IP ecosystem.
Key Patents and Their Status
The primary patent protection for Darolutamide is generally associated with Bayer. Understanding the status of Bayer's core patents is crucial for assessing the competitive environment:
- EP 2407401 B1 (European Patent): This patent, often considered a foundational patent for Darolutamide, covers the compound itself and its use in treating prostate cancer. This patent has been central to Bayer's market exclusivity.
- US Patent 8,183,415: The corresponding U.S. patent for Darolutamide and its therapeutic use.
- WO 2007/057362 A1 (International Patent Application): The PCT application from which many national and regional patents, including the European and US counterparts, likely originated.
These core patents typically cover the compound per se, methods of making the compound, and methods of using the compound for treating prostate cancer. The expiration dates of these foundational patents are critical indicators of when generic competition might emerge. For instance, if the core compound patent expires in the U.S. in 2028, generic manufacturers could potentially launch their versions of Darolutamide after that date, subject to any remaining formulation or method-of-use patents.
The Role of AR070561 within the Landscape
Patent AR070561, filed by Merck Sharp & Dohme Corp., appears to focus on specific aspects of Darolutamide formulation, particularly a defined crystalline form (Darolutamide Form I). This type of patent is often referred to as a "polymorph patent" or "form patent."
- Form Patents and Exclusivity: Polymorph patents are critical for extending market exclusivity beyond the expiration of the basic compound patent. If Darolutamide Form I has demonstrably superior properties (e.g., improved stability, dissolution rate, or manufacturability) compared to other known forms, it can provide a basis for a new period of patent protection.
- Navigating Existing IP: Merck Sharp & Dohme Corp.'s filing of AR070561 may indicate efforts to:
- Develop their own improved formulations of Darolutamide.
- Identify and patent novel, advantageous crystalline forms.
- Potentially license or acquire rights related to this specific form.
- Engage in strategic patenting to create defensive or offensive IP positions.
Potential Interplay with Generic Manufacturers
Generic manufacturers typically aim to enter the market once the primary compound patent expires. However, they must also navigate any existing valid patents on specific forms, formulations, or methods of use.
- Challenge to Form Patents: Generic companies may challenge the validity of form patents like AR070561 by demonstrating that the claimed crystalline form is obvious, not novel, or does not offer a significant advantage over known forms. This often involves extensive prior art searches and potential litigation.
- Alternative Forms: If AR070561 is granted and remains valid, generic manufacturers might seek to develop and patent their own alternative crystalline forms or formulations of Darolutamide that do not infringe upon Merck Sharp & Dohme Corp.'s claims.
Geographic Considerations
The patent landscape is geographically specific. While AR070561 is an Argentinian patent application, similar patent filings would exist in other major pharmaceutical markets, including the United States, Europe, Japan, China, and Canada. A comprehensive analysis would require examining patent filings in all relevant jurisdictions. The granted status and claims of AR070561 in Argentina would be influenced by patent examination standards and prior art available in that jurisdiction.
What are the Potential Business Implications of Patent AR070561?
The existence and potential grant of patent AR070561 have several critical implications for stakeholders in the prostate cancer therapeutic market, including originator companies, generic manufacturers, and investors.
For Originator Companies (e.g., Bayer, potentially Merck Sharp & Dohme Corp. if they have a strategic interest)
- Extended Market Exclusivity: If AR070561 is granted and covers a commercially viable and superior crystalline form of Darolutamide, it could grant Merck Sharp & Dohme Corp. or its licensees a period of market exclusivity for formulations utilizing this specific form, even after the expiration of the primary Darolutamide compound patent. This extends revenue streams and protects market share.
- Barriers to Entry: A strong patent on a key crystalline form can create significant hurdles for generic competitors. Generic companies would need to either find a way to design around the patent (e.g., by using a different crystalline form or formulation) or challenge its validity.
- Licensing Opportunities: If Merck Sharp & Dohme Corp. holds a patent on a beneficial form, it could create opportunities for licensing agreements with other pharmaceutical companies, including potentially Bayer, or for co-development.
For Generic Manufacturers
- Freedom-to-Operate Analysis: Generic companies must conduct thorough freedom-to-operate (FTO) analyses to ensure that their proposed generic products do not infringe on existing patents, including formulation and polymorph patents like AR070561.
- Patent Challenges: If AR070561 is granted and poses a significant barrier, generic companies may consider challenging its validity through post-grant opposition proceedings or invalidity lawsuits. This requires substantial legal and scientific resources.
- Development of Alternative Forms: Generic manufacturers will likely focus on developing their own non-infringing crystalline forms or formulations of Darolutamide. This may involve extensive research into the solid-state chemistry of Darolutamide to identify novel, patentable, or unpatented forms.
- Market Entry Timing: The existence and enforceability of AR070561 will influence the timing of generic market entry. If the patent is strong, generic entry may be delayed until its expiration or successful challenge.
For Investors
- Risk Assessment: Investors in pharmaceutical companies, particularly those involved in oncology or generic drug development, need to assess the IP risks and opportunities associated with key drugs like Darolutamide. The strength and scope of patents like AR070561 directly impact revenue projections and competitive landscapes.
- Valuation of IP Portfolios: The value of a pharmaceutical company's patent portfolio is a critical component of its overall valuation. Patents on specific drug forms can significantly enhance the perceived value and future earning potential of a drug.
- Strategic Investment: Understanding the patent landscape allows for more informed investment decisions, identifying companies with strong IP protection or those well-positioned to navigate complex patent challenges.
For Research & Development (R&D) Teams
- Formulation Innovation: AR070561 highlights the importance of solid-state research and formulation science in drug development. Teams may be motivated to explore new crystalline forms or salt forms to improve drug performance or secure new IP.
- Competitive Intelligence: R&D teams use patent analysis as a tool for competitive intelligence, understanding what innovations competitors are pursuing and identifying potential white spaces for their own research.
The specific impact of AR070561 will depend on its granted status, the strength of its claims, its enforceability in Argentina, and its relationship to other existing Darolutamide patents.
Key Takeaways
Patent application AR070561, filed by Merck Sharp & Dohme Corp., claims a pharmaceutical composition containing Darolutamide in a specific crystalline form (Darolutamide Form I) and its use for treating prostate cancer. This type of patent, focusing on a specific polymorphic form, can extend market exclusivity beyond the primary compound patent, creating significant implications for originator and generic pharmaceutical companies, as well as investors. The patent landscape for Darolutamide is primarily driven by originator patents held by Bayer Pharma AG, but Merck Sharp & Dohme Corp.'s filing indicates strategic IP development in formulation. Generic manufacturers must navigate these patents, potentially by challenging their validity or developing alternative, non-infringing forms, influencing market entry timing and competitive dynamics.
Frequently Asked Questions
-
What is the current legal status of patent application AR070561 in Argentina?
The precise granted status and any pending oppositions or amendments for patent application AR070561 in Argentina would require a real-time search of the Argentinian National Institute of Industrial Property (INPI) database. This analysis assumes the application is proceeding or has been granted with the described claims.
-
Does patent AR070561 prevent the use of Darolutamide for prostate cancer treatment in Argentina?
If granted and deemed valid, AR070561 would prevent the commercialization of pharmaceutical compositions containing Darolutamide in the specific crystalline form claimed, for the treatment of prostate cancer in Argentina, by parties other than the patent holder or its licensees. It does not prevent all uses of Darolutamide if other forms or methods are not covered.
-
What are the differences between Darolutamide Form I and other potential crystalline forms?
The patent claims specify unique X-ray powder diffraction (XRPD) patterns for Darolutamide Form I. Differences typically lie in physical properties such as solubility, dissolution rate, stability, hygroscopicity, and manufacturability, which can impact the drug's efficacy and formulation.
-
How long would patent AR070561 potentially provide exclusivity in Argentina?
A granted patent in Argentina generally has a term of 20 years from the filing date. However, specific circumstances like patent term extensions or supplementary protection certificates (if applicable in Argentina) can alter this duration. The filing date of AR070561 is required to determine the precise expiration date.
-
Can generic manufacturers legally sell Darolutamide in Argentina if the primary compound patent expires but AR070561 is still active?
Generic manufacturers can only sell Darolutamide in Argentina if their product does not infringe any active and valid patents, including formulation or polymorph patents like AR070561. If AR070561 is valid, generic manufacturers would need to use a different, non-infringing crystalline form or formulation, or successfully invalidate AR070561.
Citations
[1] Merck Sharp & Dohme Corp. (n.d.). Pharmaceutical composition comprising crystalline N-{(2S)-1-[6-(3-chloro-4-fluorophenyl)-2-methylpyrimidin-4-yl]-2-hydroxypropyl}-5-(1,3-oxazol-2-yl)pyridin-2-amine (Patent Application No. AR070561). Instituto Nacional de la Propiedad Industrial (INPI).
